Sanuwave Health, INC

Sanuwave Health announced preliminary Q2 2026 revenues are expected to be between $9.6 million and $9.8 million, exceeding its revised guidance.

Sanuwave Health announced updated revenue guidance for Q2 2026, expecting $8.5 - $9.5 million, below previous projections, due to market disruption impacting Ultramist system sales.

Sanuwave Health stockholders elected five directors and ratified the appointment of Baker Tilly US, LLP as the company's independent auditor.

Sanuwave Health announced first-quarter 2026 financial results, showing a 3.1% revenue increase to $9.6 million, with guidance for continued growth.

Sanuwave Health expects Q1 2026 revenue between $9.6 million and $9.7 million, reflecting a 3-4% year-over-year increase.

Sanuwave Health, Inc. announced record revenues for both the fourth quarter and full year 2025, driven by strong UltraMIST system and consumables sales.

SANUWAVE Health reports a 3% revenue increase to $9.6 million and a reduced net loss of $1.4 million for the first quarter of 2026, driven by higher disposable sales and a favorable year-over-year comparison.

SANUWAVE Health, Inc. reported a significant increase in revenue and net income for the third quarter and nine months ended September 30, 2025, driven by UltraMIST sales and a strategic debt refinancing.

SANUWAVE Health, Inc. reported significant revenue growth and improved gross margins for Q2 2025, but faces substantial doubt about its ability to continue as a going concern due to maturing debt and ongoing internal control weaknesses.

SANUWAVE Health, Inc. reports a significant 61% increase in revenue for the first quarter of 2025, driven by growth in UltraMIST disposables and systems, and announces its listing on The Nasdaq Global Market.

SANUWAVE Health experienced a significant 89% increase in revenue for the third quarter of 2024 compared to the same period last year, while still navigating financial difficulties.

SANUWAVE Health, Inc. saw a 53% increase in revenue and achieved net income for the second quarter of 2024, driven by strong sales of its UltraMIST system.

SANUWAVE Health, Inc. announced a significant financial turnaround in its 2025 annual report, achieving net income and substantial revenue growth following a debt refinancing and prior period restatements.

SANUWAVE Health achieved a 60% increase in revenue for 2024, driven by UltraMIST sales, but net losses continued due to changes in derivative valuations and debt related costs.

SANUWAVE Health, Inc. saw a 22% increase in revenue in 2023 and is working towards completing a merger with SEP Acquisition Corp.

SANUWAVE Health, Inc. reports that Director Jeffrey Blizard acquired stock options, indicating potential future equity participation.

Director Ian D. Miller of SANUWAVE Health, Inc. reported the acquisition of stock options.

Director James Tyler reported the acquisition of 5,524 stock options for SANUWAVE Health, Inc. (SNVW) with an exercise price of $10, exercisable from June 30, 2026, to June 30, 2031.

SANUWAVE Health, Inc. reports that CEO Morgan C. Frank acquired 5,524 stock options, fully vested at grant, with an exercise price of $10.

Opaleye Management Inc. reported the sale of 16,469 shares of SANUWAVE Health, Inc. common stock across multiple transactions.

Director James Tyler acquired stock options for 3,208 shares of SANUWAVE Health, Inc. under a Rule 10b5-1(c) plan.

SANUWAVE Health, Inc. has announced its annual stockholder meeting for June 11, 2026, to vote on director elections, auditor ratification, and executive compensation.

SANUWAVE Health, Inc. has filed its Definitive Proxy Statement (DEFA14A) with the U.S. Securities and Exchange Commission.

SANUWAVE Health, Inc. is seeking shareholder approval for director elections, auditor ratification, and a significant increase in its equity incentive plan, while grappling with persistent financial losses, material weaknesses in internal controls, and a history of delinquent insider trading reports.

SANUWAVE Health is soliciting stockholder consent to approve a reverse stock split and a new equity incentive plan to address potential default under convertible notes and pursue Nasdaq uplisting.

SANUWAVE Health, Inc. has filed a registration statement for the potential resale of up to 2,887,156 shares of its common stock by existing stockholders.

Manchester Management and affiliated entities have filed an amended Schedule 13D, disclosing a slight reduction in their beneficial ownership of SANUWAVE Health, Inc. common stock.

Manchester Management and affiliated entities have increased their beneficial ownership in SANUWAVE Health, Inc. to 11.1% of common stock, reiterating an investment-focused approach.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 309,948 shares of SANUWAVE Health, Inc. common stock, representing 3.6% of the outstanding shares.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of SANUWAVE Health, Inc. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in SANUWAVE Health Inc. following an internal realignment.

BlackRock, Inc. has reported a passive 5.6% beneficial ownership stake in SANUWAVE HEALTH INC common stock.

Solas Capital Management and Frederick Tucker Golden have amended their beneficial ownership in SANUWAVE Health, Inc. to 3.5% of common stock.

The Vanguard Group has reported beneficial ownership of 5.19% of SANUWAVE Health Inc.'s Common Stock as of June 30, 2025.